⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024Open Access

Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Monica F. Chen Soo‐Ryum Yang Jessica J. Tao Antoine Desîlets Eli L. Diamond Clare Wilhelm Ezra Y. Rosen Yixiao Gong Kerry Mullaney Jean Torrisi Robert J. Young Romel Somwar Helena A. Yu Mark G. Kris Gregory J. Riely Maria E. Arcila Marc Ladanyi Mark T.A. Donoghue Neal Rosen Rona Yaeger Alexander Drilon Yonina R. Murciano‐Goroff Michael Offin

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplemental Table 1. Baseline characteristics of patients with de novo and acquired BRAF fusions.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db643587533b0d https://doi.org/10.1158/1078-0432.26926564.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024
2Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024
3Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024
4Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024
5Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024

Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024
Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024